4 minute read
Dec. 12, 2023
A PARP1i, GLP-1Ra, and Other Million-Dollar Molecules from Nov. ‘23
Author:
Editor:
Several multi-million dollar acquisitions or license agreements took place in November 2023 for hot drug targets, with assets from selective PARP1 inhibitors to GLP1R agonists, and others. This recent news roundup highlights the notable acquisitions by pharma companies for rights to molecules in a range of different indications, with illustrative patent examples for undisclosed structures.
Loading...
